Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells
Autor: | Kris L. Shogren, Andre J. van Wijnen, Scott M. Riester, Jann N. Sarkaria, Ann C. Mladek, Michael J. Yaszemski, Mario Galindo, Carl T. Gustafson, Shiv K. Gupta, Tewodros Mamo, Avudaiappan Maran |
---|---|
Rok vydání: | 2017 |
Předmět: |
musculoskeletal diseases
0301 basic medicine DNA damage DNA repair Cell Biophysics Cell Biology Cell cycle Biology medicine.disease Biochemistry 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Cell culture 030220 oncology & carcinogenesis Immunology Cancer research medicine Osteosarcoma Radiosensitizing Agent Molecular Biology DNA-PKcs |
Zdroj: | Biochemical and Biophysical Research Communications. 486:307-313 |
ISSN: | 0006-291X |
DOI: | 10.1016/j.bbrc.2017.03.033 |
Popis: | Osteosarcoma survival rate has not improved over the past three decades, and the debilitating side effects of the surgical treatment suggest the need for alternative local control approaches. Radiotherapy is largely ineffective in osteosarcoma, indicating a potential role for radiosensitizers. Blocking DNA repair, particularly by inhibiting the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS), is an attractive option for the radiosensitization of osteosarcoma. In this study, the expression of DNA-PKCS in osteosarcoma tissue specimens and cell lines was examined. Moreover, the small molecule DNA-PKCS inhibitor, KU60648, was investigated as a radiosensitizing strategy for osteosarcoma cells in vitro. DNA-PKCS was consistently expressed in the osteosarcoma tissue specimens and cell lines studied. Additionally, KU60648 effectively sensitized two of those osteosarcoma cell lines (143B cells by 1.5-fold and U2OS cells by 2.5-fold). KU60648 co-treatment also altered cell cycle distribution and enhanced DNA damage. Cell accumulation at the G2/M transition point increased by 55% and 45%, while the percentage of cells with >20 γH2AX foci were enhanced by 59% and 107% for 143B and U2OS cells, respectively. These results indicate that the DNA-PKCS inhibitor, KU60648, is a promising radiosensitizing agent for osteosarcoma. |
Databáze: | OpenAIRE |
Externí odkaz: |